Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
Full metadata record
|dc.identifier.citation||Annals of Pharmacotherapy, 2005; 39(1):119-127||en|
|dc.description.abstract||<h4>Objective</h4>To review the literature relating to immunosuppressant drug measurement as performed in therapeutic drug monitoring laboratories associated with transplantation centers and consider whether the assay methods widely used for patient dosage management achieve acceptable quality criteria in the context of other sources of variability with these drugs.<h4>Data sources</h4>Articles used were accessed primarily through MEDLINE, as well as references cited in related publications. Searches were restricted to organ transplantation in humans.<h4>Study selection and data extraction</h4>Emphasis was placed on the literature relating to the quality of immunosuppressant drug assays, their limitations, and evidence of clinical benefit in dosage individualization.<h4>Data synthesis</h4>There is a dilemma evident between the quality of the analytical services offered by some diagnostic immunoassay manufacturers and the ability of a significant number of clinical laboratories globally to select only appropriate assay methods.<h4>Conclusions</h4>In many cases, clinical laboratories fail to meet the reasonable clinical expectations required for interpretation of immunosuppressant drug assay results as an adjunct to optimal dosage individualization and patient care.||en|
|dc.publisher||Harvey Whitney Books Co||en|
|dc.subject||Humans; Mycophenolic Acid; Sirolimus; Tacrolimus; Cyclosporine; Immunosuppressive Agents; Drug Monitoring; Transplantation; Quality Control; Laboratories||en|
|dc.title||Immunosuppressant drug monitoring: Is the laboratory meeting clinical expectations?||en|
|Appears in Collections:||Pharmacology publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.